1-12 of 12
Christophe Schmitt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Clinical Trials & Observations
Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat
Journal: Blood
Blood (2024) 143 (14): 1355–1364.
https://doi.org/10.1182/blood.2023021832
Published: 2024
Includes: Supplemental data
Journal Articles

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Anna Kiialainen, Steven Pipe, Karin Fijnvandraat, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Christophe Dhalluin, Michaela Lehle, Peter Collins
Journal: Blood
Blood (2023) 142 (Supplement 1): 1238.
https://doi.org/10.1182/blood-2023-173015
Published: 2023
Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat
Journal: Blood
Blood (2023) 142 (Supplement 1): 505.
https://doi.org/10.1182/blood-2023-177963
Published: 2023
Journal Articles

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat
Journal: Blood
Blood (2022) 140 (Supplement 1): 457–459.
https://doi.org/10.1182/blood-2022-157264
Published: 2022
Journal Articles

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, Christophe Schmitt, Cedric Hermans, Giuliana Ventriglia, Jerzy Windyga, Anna Kiialainen, Roseline d'Oiron, Paul Moorehead, Vanda Teodoro, Amy D. Shapiro, Johannes Oldenburg
Journal: Blood
Blood (2021) 138 (Supplement 1): 343.
https://doi.org/10.1182/blood-2021-146009
Published: 2021
Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Clinical Trials & Observations
Michael U. Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Victor Jiménez-Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg
Journal: Blood
Blood (2021) 137 (16): 2231–2242.
https://doi.org/10.1182/blood.2020009217
Published: 2021
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Michael U. Callaghan, MD, Claude Négrier, Ido Paz-Priel, MD, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, MD, Rebecca Kruse-Jarres, MD, Maria Elisa Mancuso, Markus Niggli, Peter Kuebler, Nives Selak Bienz, Midori Shima, MD, Victor Jimenez-Yuste, MDcal Degree. PhD, Christophe Schmitt, Elina Asikanius, Gallia Levy, Steven W. Pipe, MD, Johannes Oldenburg
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-137438
Published: 2020
Journal Articles

Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies

Candice Jamois, PharmD, Doreen Anders, Benjamin M. Beckermann, PhD, Magali Genevray, MD, Kirsten Mundt, PhD, Claire Petry, Joy Yang, Nastya Kassir, Christophe Schmitt
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-136419
Published: 2020
Journal Articles

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Clinical Trials & Observations
Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Jr, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen, Michelle Y. Doral, Lilyan Y. Wright, Christophe Schmitt, Gallia G. Levy, Midori Shima, Maria Elisa Mancuso
Journal: Blood
Blood (2019) 134 (24): 2127–2138.
https://doi.org/10.1182/blood.2019001869
Published: 2019
Includes: Supplemental data
Journal Articles

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Guy Young, Ri Liesner, Robert F. Sidonio, Jr., Johannes Oldenburg, Victor Jimenez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Tiffany Chang, Marianne Uguen, Michelle Doral, Christophe Schmitt, Gallia G. Levy, Midori Shima, MD PhD, Maria Elisa Mancuso
Journal: Blood
Blood (2018) 132 (Supplement 1): 632.
https://doi.org/10.1182/blood-2018-99-118153
Published: 2018
Journal Articles

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Ido Paz-Priel, Tiffany Chang, Elina Asikanius, Sammy Chebon, Thomas Emrich, Elena Fernandez, Peter Kuebler, Christophe Schmitt
Journal: Blood
Blood (2018) 132 (Supplement 1): 633.
https://doi.org/10.1182/blood-2018-99-118492
Published: 2018
Journal Articles

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Guy Young, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, Christophe Schmitt, Gallia G. Levy, Midori Shima, MDPhD, Johnny Mahlangu
Journal: Blood
Blood (2017) 130 (Supplement 1): 85.
https://doi.org/10.1182/blood.V130.Suppl_1.85.85
Published: 2017